Josh Muntner has more than 25 years of experience in healthcare investment banking and corporate finance, and he has played a lead role in a wide range of healthcare-related transactions. He serves as chief financial officer of Imvax, a Philadelphia-based company with a unique platform technology focused on delivering personalized, whole tumor-derived immunotherapies across a range of solid tumors. From 2018 to 2021, Mr. Muntner served as chief financial officer at Mesoblast Limited (ASX: MSB) (Nasdaq: MESO), a late-stage biotechnology company with global operations. Prior to that, Mr. Muntner served as senior vice president of business development at ContraFect Corporation (Nasdaq: CFRX), a biotechnology company developing novel anti-infective therapies. Prior to his work in-house in biotech companies, Mr. Muntner began his career as an investment banker providing financing and strategic advisory services to early-stage life sciences companies. He worked as an investment banker for over 15 years, most recently serving as Managing Director and Co-Head of Healthcare Investment Banking at Janney Montgomery Scott. Prior to this, he worked at Oppenheimer & Co. and its U.S. predecessor, CIBC World Markets. He holds a BA from Carnegie Mellon University and an MBA from the Anderson School of Management at the University of California, Los Angeles.